{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:56:11Z","timestamp":1769734571068,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.autrev.2008.11.002","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T13:34:41Z","timestamp":1227706481000},"page":"266-273","source":"Crossref","is-referenced-by-count":134,"title":["Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients"],"prefix":"10.1016","volume":"8","author":[{"given":"Ennio Giulio","family":"Favalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Desiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Bobbio","family":"Pallavicini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2008.11.002_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2008.11.002_bib2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2008.11.002_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4\u00a0year extended study","volume":"65","author":"Weinblatt","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.002_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2008.11.002_bib5","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2008.11.002_bib6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/art.1780140119","article-title":"Infections in rheumatoid arthritis","volume":"14","author":"Baum","year":"1971","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib8","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study","volume":"9","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 74","key":"10.1016\/j.autrev.2008.11.002_bib9","first-page":"35","article-title":"Why does tumor necrosis factor targeted therapy reactivate tuberculosis?","volume":"32","author":"Ehlers","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.002_bib10","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib11","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/00365540601071867","article-title":"Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab","volume":"39","author":"Kalyoncu","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.autrev.2008.11.002_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.semarthrit.2006.08.004","article-title":"Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis","volume":"36","author":"Lassoued","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.rmed.2005.09.020","article-title":"Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area","volume":"100","author":"Jain","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.autrev.2008.11.002_bib15","first-page":"2432","article-title":"Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab","volume":"32","author":"Fabre","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2008.11.002_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2008.11.002_bib17","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2008.11.002_bib21","unstructured":"Sarzi-Puttini P, Antivalle M, Marchesoni A, Favalli EG, Gorla R, Fillipini M, et al. Efficacy and safety of anti-TNF agents in the Lombardy Rheumatoid Arthritis Network (LORHEN). Reumatismo in press."},{"issue":"Suppl 2","key":"10.1016\/j.autrev.2008.11.002_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ard.61.suppl_2.ii2","article-title":"Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)","volume":"61","author":"Furst","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2008.11.002_bib23","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-\u03b1 therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2008.11.002_bib25","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1086\/345799","article-title":"Tumor necrosis factor-\u03b1-converting enzyme: its role in community-acquired pneumonia","volume":"186","author":"Greene","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.autrev.2008.11.002_bib26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Association with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.1995.tb08666.x","article-title":"Tumour necrosis factor \u03b1 is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression","volume":"132","author":"Groves","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2008.11.002_bib28","doi-asserted-by":"crossref","first-page":"307324","DOI":"10.2165\/00002018-200427050-00003","article-title":"Safety of tumour necrosis factor-\u03b1 antagonists","volume":"27","author":"Khanna","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2008.11.002_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.autrev.2008.11.002_bib30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.autrev.2008.11.002_bib31","unstructured":"The World Health Organization; 2005 [http:\/\/www.who.int\/globalatlas\/dataQuery]."},{"issue":"Suppl 1","key":"10.1016\/j.autrev.2008.11.002_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"Wallis","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2008.11.002_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","article-title":"Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept","volume":"25","author":"Fleischmann","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.autrev.2008.11.002_bib34","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2008.11.002_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2007.03.003","article-title":"Biological and clinical effects of anti-TNFalpha treatment","volume":"7","author":"Valesini","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2008.11.002_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2007.03.001","article-title":"Inflammatory molecules: a target for treatment of systemic autoimmune diseases","volume":"7","author":"Tincani","year":"2007","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997208002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997208002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T04:50:35Z","timestamp":1545627035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997208002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1568997208002206"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2008.11.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}